KFSHRC Advances Smart Hospital Transformation through AI and Emerging Technologies
RIYADH, Saudi Arabia, June 13, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) continues to redefine global healthcare through its Smart Hospital initiative, leveraging AI, simulation, and immersive technologies across its departments. These technologies have supported KFSHRC to enhance workforce training, clinical care, and operational efficiency.
The Academic & Training Affairs (ATA) division is leading this transformation, deploying next-generation tools such as simulation labs, e-learning, and virtual reality (VR) to deliver hands-on, immersive training. These technologies allow healthcare professionals to rehearse complex procedures from emergency care to surgical planning, strengthening clinical preparedness and patient safety.
The Patient Flow & Capacity Command Centre enhances operational efficiency by applying AI to forecast demand, manage resources, and monitor patient flow in real time. Since its launch, the Centre has completed over 170,000 interventions, cutting bed wait times from 32 to 6 hours and reducing emergency delays by 14%. In 2024 alone, the hospital received over 46,000 new patients and processed more than 79,000 referrals. Smart tools, such as the Noor robot, enhance the patient experience by providing real-time assistance and improving access to services.
Across departments such as Radiology, Pathology, Genomics, and Oncology, AI enhances diagnosis, interpretation, early interventions and personalized care for complex diseases. Driving these innovations is KFSHRC's Centre for Healthcare Intelligence (CHI), which has developed over 20 AI applications in medical imaging, clinical decision support, and operations. In partnership with the Saudi Commission for Health Specialties, CHI also leads national AI training programs to build future-ready digital health talent. At the 2024 GAIN Summit CHI unveiled a generative AI platform to synthesize patient data, accelerate diagnostics, and streamline triage.
KFSHRC ranks among Saudi Arabia's top 20 government entities in the 2025 Technology Adoption Readiness Index and received the 2024 Zimam Best AI Program Award, recognizing its leadership in AI, robotic surgery, and digital innovation. Additionally, it was included in the World's Best Smart Hospitals list for 2025 by Newsweek magazine.
It is noteworthy that KFSHRC has been ranked first in the Middle East and Africa and 15th globally in the list of the world's top 250 Academic Medical Centres for the third consecutive year and recognised as the most valuable healthcare brand in the Kingdom and the Middle East, according to the 2025 Brand Finance rankings. For more information, visit www.kfshrc.edu.sa or contact our media team at mediacoverage@kfshrc.edu.sa.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/41a82b38-59b4-485a-b93c-33484c369397Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
8 hours ago
- Business Insider
TruGolf Announces Acquisition of mlSpatial
Salt Lake City, Utah, June 11, 2025 (GLOBE NEWSWIRE) -- TruGolf Holdings, Inc. (NASDAQ: TRUG), a leading golf technology company, has announced that it has executed a definitive agreement to acquire mlSpatial, a renowned AI and machine learning engineering firm. This strategic acquisition aims to advance the integration of artificial intelligence within TruGolf's industry-leading products, including the Apogee Launch Monitor, Launchbox, Multisport Arcade, and E6 Apex. The collaboration between TruGolf and mlSpatial began in March 2024 with a licensing agreement to co-develop an AI engine enhancing the 9-axis spin accuracy of TruGolf's Apogee Launch Monitor. Building upon this successful partnership, the full acquisition of mlSpatial will enable TruGolf to seamlessly incorporate advanced AI technologies across its entire product suite, delivering unparalleled user experiences, training suggestions, and player insights. 'We are very excited to bring mlSpatial and its AI and machine learning technology into the TruGolf family,' said Chris Jones, TruGolf CEO. He continued, 'Acquiring mlSpatial marks a significant milestone in our commitment to revolutionize golf simulation through cutting-edge AI integration. This acquisition empowers us to explore innovative applications of AI across our ecosystem, enhancing realism and interactivity for our users while lowering development costs.' Josh Pomazal, founder of mlSpatial, expressed enthusiasm about the acquisition: "We're excited to leverage TruGolf's extensive real-time data, collected daily, to continually refine our products with the advanced machine learning and AI models we've developed over the years." This acquisition solidifies our deep commitment to innovation and aligns with the broader industry trend of significant investments in AI infrastructure. Notably, in January 2025, President Donald Trump announced a private-sector initiative, the Stargate Project, aiming to invest up to $500 billion in AI infrastructure within the United States. This substantial investment underscores the rapid progress and importance of AI technologies across various sectors. TruGolf's acquisition of mlSpatial positions the company at the forefront of AI-driven innovation in golf simulation, promising enhanced performance and immersive experiences for enthusiasts worldwide. For more information, please visit About TruGolf Holdings TruGolf is a golf technology company, committed to making golf, easy. From innovative uses for AI to build content and enhance its image and spatial analysis, to gamified golf improvement plans, TruGolf is an industry leader in the growing technological revolution in the sport of golf. Since its founding, TruGolf has redefined what is possible in golf through technology. TruGolf's suite of Hardware, Software, and Web Products make it easier to Play, Improve, and Enjoy the game of golf. Forward-Looking Statements Some of the statements in this release are forward-looking statements, which involve risks and uncertainties. Forward-looking statements include, without limitation, whether the Company's compliance plan will be accepted by Nasdaq and the Company's expected future cash needs. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ''believes,'' ''estimates,'' ''anticipates,'' ''expects,'' ''plans,'' ''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,'' ''might,'' ''will,'' ''should,'' ''approximately'' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the SEC, which are available on the SEC's website,
Business Upturn
10 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
10 hours ago
- Business Upturn
Unplugged Performance to Showcase Tesla Builds at Electrify Expo – North America's Largest EV Festival
LOS ANGELES, June 20, 2025 (GLOBE NEWSWIRE) — Unplugged Performance, the world leader in Tesla-focused performance upgrades, is headed to Electrify Expo, North America's premier electric vehicle lifestyle event. Taking place this weekend June 21st & 22nd, Electrify Expo invites EV enthusiasts, media, and families for an immersive look at the future of electrification. Unplugged Performance will be displaying four of its latest builds at the show, each with upgrades tailored for parts performance, durability, and everyday driving. Advertisement Tesla Model 3 Performance 'Red Rocket' Track Build Built to dominate the track and the streets, car features our: UP Race Pro Coilovers with Adaptive Canceller UP Carbon Fiber Front Aero Kit + Rear Dual Spoiler and Wing Set Up + Rear Spats and Diffuser 18×10.9 UP-03 Forged Wheels Yokohama ADVAN A052 295/35R18 Tires Satin Red 2026 Tesla Model Y Off-Road/Street Build Adventure-ready, this MY build includes our: UP 35mm Leveling Lift Kit Off-Road Spec 18″ UP-05 Forged Wheels Off-Road Sway Bar + End Links Yokohama GEOLANDAR Tires UP INVINCIBLE® Cybertruck Street Build The ultimate Tesla Cybertruck to take on anything on earth and beyond with: HD Front & Rear Bumpers, Bull Bar, Rock Sliders Carbon Fiber Hood w/ 50' LED Light Bar Side Sail Panel MOLLE Rack System 22' CYBRHEX Forged Wheels Yokohama GEOLANDAR Tires Quicksilver 2026 Tesla Model Y Off-Road/Street Build Ready for the streets, this MY build includes our: 22' UP Forged CYBRHEX Wheels Moderate option Dual Rate Lowering Springs Yokohama Parada Spex-X Tires Learn more about our products at Media Contact: Bryan Benitez [email protected] Photos accompanying this announcement are available at: Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
